Nausea, vomiting, constipation, and a small but real list of serious risks — here is what the prescribing data actually show about semaglutide, how symptoms shift across the titration schedule, and which warning signs mean stopping the drug is not optional.
The most common Ozempic side effects are gastrointestinal: nausea in roughly 20% of patients, diarrhea in about 13%, vomiting in about 9%, and constipation in about 6%, according to FDA prescribing information.[1] Most are mild, peak during the first 8–12 weeks of dose escalation, and settle as the body adapts. Rare but serious effects include pancreatitis, gallbladder disease, and bowel obstruction.
- Why Ozempic causes side effects at all
- The most common side effects, by the numbers
- Serious side effects that are rare but real
- How the side effect profile changes over time
- Practical ways to reduce side effects
- Who should not take Ozempic
- Red flags: when to call your doctor or go to the ER
- How Ozempic compares with other GLP-1 drugs
- Frequently asked questions
Why Ozempic Causes Side Effects at All
Semaglutide — sold as Ozempic for type 2 diabetes and as Wegovy for weight management — is a GLP-1 receptor agonist that mimics a gut hormone your body already makes. That mimicry is the entire point of the drug, and it is also the source of nearly every side effect on the label. Understanding where the drug acts explains why nausea dominates the symptom list and why constipation is nearly as common as vomiting.
Three receptor populations drive most of what patients feel:
- The hypothalamus. GLP-1 receptors here reduce appetite signaling and slow the reward response to food, which is why hunger drops and why some people lose interest in eating altogether.
- The area postrema. This is a small structure at the base of the fourth ventricle that sits outside the blood–brain barrier and functions as the brain's chemical vomit detector. GLP-1 receptors are dense there, and stimulating them is the direct mechanism behind semaglutide-associated nausea. The drug is not "upsetting the stomach" in the way a spoiled meal would — it is activating the emetic circuit directly.
- The enteric nervous system. GLP-1 slows gastric emptying and reduces intestinal motility, keeping food in the stomach longer. That extends fullness after meals, which helps with appetite control, but it also produces bloating, early satiety, reflux, and constipation.
There is a fourth, less discussed effect: a modest rise in resting heart rate. Pooled trial data show an increase of roughly 2 to 3 beats per minute on semaglutide compared with placebo, an average that is clinically unimportant for most people but noticeable for those with palpitations or anxiety.[1]
The clinical implication matters: because these effects are mechanism-driven rather than idiosyncratic, they follow a predictable pattern. Symptoms cluster around dose increases and then attenuate. A patient who is nauseated at week three is experiencing the expected pharmacology, not a sign that something has gone wrong — provided the severity stays within the bounds described later in this article.
The Most Common Side Effects, by the Numbers
Gastrointestinal complaints account for the overwhelming majority of reported adverse events in the semaglutide trials. The table below reflects rates reported in the Ozempic prescribing information across the SUSTAIN development program, comparing semaglutide with placebo.[1]
| Side effect | Approximate rate (semaglutide) | Placebo rate | Typical pattern |
|---|---|---|---|
| Nausea | ~20% | ~7% | Peaks 1–2 weeks after each dose increase, wanes by week 8–12 |
| Diarrhea | ~13% | ~8% | Often intermittent, can alternate with constipation |
| Vomiting | ~9% | ~3% | Usually follows nausea; most common in first month |
| Constipation | ~6–7% | ~2% | Can persist longer than nausea; worsens with low fluid intake |
| Abdominal pain | ~6% | ~2% | Cramping, often post-prandial |
| Dyspepsia / reflux | ~4–5% | ~2% | Worse with large or high-fat meals |
| Headache | ~2–3% | ~2% | Often related to dehydration or skipped meals |
| Fatigue | ~2% | ~1% | Commonly driven by low caloric intake early on |
| Injection-site reactions | ~2% | ~2% | Mild redness or bruising, self-limited |
Two details in that table deserve emphasis. First, diarrhea is nearly as frequent as nausea in real-world reports even though nausea gets the headlines — and constipation, which is under-reported in trials, becomes the dominant complaint for many patients after the first two months. Second, these are pooled averages across doses; the 0.25 mg starting dose produces far fewer symptoms than the 1 mg and 2 mg maintenance doses, which is exactly why the label specifies stepwise escalation rather than starting at a therapeutic dose.
Symptoms outside the gut
Beyond the GI tract, patients commonly describe a flattened appetite that tips into food aversion, a metallic or altered taste, and early fullness so pronounced that finishing half a normal portion feels impossible. Low blood sugar is not a direct effect of semaglutide on its own — GLP-1 agonists are glucose-dependent and rarely cause hypoglycemia as monotherapy — but the risk rises sharply when Ozempic is combined with insulin or a sulfonylurea such as glipizide or glimepiride. The ADA Standards of Care in Diabetes—2026 explicitly advises reducing the dose of the insulin secretagogue or insulin at initiation to reduce this risk.[2]
Not every GI symptom on Ozempic is "just the drug." Persistent vomiting, pain that radiates into the back, or a distended abdomen with no bowel movement for days are not titration effects — they are the presentations of pancreatitis, gallbladder disease, and ileus respectively. The difference between a manageable side effect and a medical emergency is usually duration and severity, not the symptom itself.
Serious Side Effects That Are Rare but Real
Serious adverse events on semaglutide are uncommon — most fall well below 1% in trial populations — but each carries enough consequence that the FDA label addresses it explicitly. Knowing them is what allows a patient to distinguish an unpleasant week from a dangerous one.
Acute pancreatitis
Post-marketing reports link GLP-1 receptor agonists to acute pancreatitis, and the Ozempic label instructs discontinuation if pancreatitis is suspected.[1] The classic presentation is severe, constant epigastric pain boring through to the back, often with vomiting that does not relieve the pain. A history of prior pancreatitis, gallstones, or heavy alcohol use raises baseline risk and warrants a careful conversation before starting therapy.
Gallbladder disease
Rapid weight loss is itself a cholelithiasis risk factor, and GLP-1 therapy compounds it by slowing gallbladder emptying. Cholelithiasis and cholecystitis appear more frequently in semaglutide-treated patients than in placebo groups. Right-upper-quadrant pain after fatty meals, fever, or jaundice are the signals to watch for.
Bowel obstruction and severe gastroparesis
Delayed gastric emptying is a therapeutic feature of the drug; in a minority of patients it becomes pathological. Post-marketing surveillance has captured reports of ileus and severe gastroparesis, sometimes after years of stable use. Vomiting that prevents fluid intake, abdominal distension, and complete absence of bowel movements should be evaluated urgently rather than managed at home.
Diabetic retinopathy complications
In the SUSTAIN-6 cardiovascular outcomes trial, patients receiving semaglutide experienced more retinopathy complications than those on placebo — a finding plausibly driven by rapid glycemic improvement rather than direct retinal toxicity.[1] Patients with pre-existing proliferative retinopathy or poorly controlled diabetes should have a dilated eye exam before or shortly after starting, and the ADA recommends ophthalmologic monitoring during rapid glucose lowering.[2]
Acute kidney injury
Kidney injury on semaglutide is almost always secondary to volume depletion from prolonged vomiting or diarrhea rather than a direct nephrotoxic effect. The label advises monitoring renal function in patients reporting severe GI symptoms, particularly those already living with chronic kidney disease or taking diuretics and ACE inhibitors.[1]
Thyroid C-cell tumors: the boxed warning
Ozempic carries an FDA boxed warning for the risk of thyroid C-cell tumors, based on rodent studies in which semaglutide caused dose-dependent C-cell hyperplasia and medullary thyroid carcinoma. Whether this translates to human risk is not established, and clinical evidence to date has not confirmed an increase in medullary thyroid cancer among treated patients. The warning nonetheless makes a personal or family history of medullary thyroid carcinoma or MEN2 (multiple endocrine neoplasia type 2) an absolute contraindication.[1]
Aspiration risk during anesthesia
Because gastric emptying is slowed, residual stomach contents can persist for hours after the last meal. The American Society of Anesthesiologists has issued guidance on perioperative management of GLP-1 receptor agonists, including consideration of holding the drug or using a liquid diet before elective procedures.[4] Telling your anesthesiologist that you take semaglutide is not optional — it directly changes how your airway is managed.
Suicidal thoughts: what the reviews found
Reports of suicidal ideation in patients on GLP-1 drugs prompted formal reviews. The FDA's 2024 preliminary evaluation found no evidence that GLP-1 receptor agonist use causes suicidal thoughts or actions, and the European Medicines Agency's PRAC reached a similar conclusion.[3] That does not mean mood changes should be ignored — appetite, weight, and glycemic shifts are significant life changes, and any new or worsening depression warrants clinical attention.
How the Side Effect Profile Changes Over Time
Ozempic is not a steady-state drug from day one. It is titrated upward over months, and every increase resets the adaptation clock. Charting that trajectory is the single most useful thing a patient can do to anticipate what is coming.
"Nearly every GI complaint on semaglutide is dose-dependent and time-limited. The clinician's job is to slow the titration enough that the patient can stay on the drug long enough to benefit from it."
Clinical consensus reflected in ADA Standards of Care—2026
Practical Ways to Reduce Side Effects
Most of the strategies below are low-tech and cost nothing, and clinicians who prescribe GLP-1 drugs regularly report that they meaningfully change who stays on therapy. None of them require stopping the medication.
Four to six weeks after each dose increase, symptoms should be trending down, not plateaued. Meals are smaller but protein-containing. Bowel movements remain regular. Weight is dropping at roughly 0.5–1% of body weight per week rather than in dramatic spurts, which reduces gallstone and muscle-loss risk. If that picture does not describe your experience, the titration plan — not the drug — is usually what needs adjusting.
Two patterns cause most avoidable discontinuations. The first is jumping doses on schedule regardless of symptoms, when the label explicitly allows a longer stay at a lower dose. The second is under-eating deliberately to accelerate weight loss — which produces more nausea, more fatigue, more hair shedding, and greater lean-mass loss than the drug would cause on its own.
Who Should Not Take Ozempic
Some of these are absolute contraindications; others are conditions that require a risk–benefit conversation before the first prescription. Expand each for the clinical reasoning.
Personal or family history of medullary thyroid carcinoma or MEN2
This is an absolute contraindication listed in the FDA boxed warning. Rodent studies showed dose-dependent thyroid C-cell tumors with semaglutide, and while human causality has not been established, the theoretical risk is serious enough that anyone with a personal or family history of medullary thyroid carcinoma — or multiple endocrine neoplasia syndrome type 2 — should not receive the drug.[1]
Pregnancy, breastfeeding, or plans to conceive within two months
Semaglutide is not recommended during pregnancy, and the label advises discontinuing at least two months before a planned pregnancy because of the drug's long half-life. Weight loss alone is not a reason to continue therapy through pregnancy. Effective contraception is advised for people of childbearing potential who are taking Ozempic.
A history of pancreatitis
Not an absolute contraindication, but a substantial caution. Patients with prior acute or chronic pancreatitis, gallstones, or significant alcohol use have a higher baseline risk, and recurrence on a GLP-1 agonist is difficult to distinguish from idiopathic disease. Many endocrinologists choose a different drug class in this group.
Severe gastroparesis or a history of bowel obstruction
Because the drug's core mechanism is slowing gastric emptying and gut motility, pre-existing severe gastroparesis or prior obstruction makes symptoms both more likely and more dangerous. The label describes post-marketing reports of ileus, and this population is the least able to tolerate it.
Type 1 diabetes
Ozempic is not indicated for type 1 diabetes and is not a substitute for insulin. GLP-1 agonists do not preserve beta-cell function enough to replace insulin in type 1 disease, and using them in place of insulin risks diabetic ketoacidosis.
Pre-existing proliferative diabetic retinopathy
Not a contraindication, but a flag for ophthalmology referral. The SUSTAIN-6 trial showed more retinopathy complications with semaglutide, likely mediated by rapid glycemic improvement. Anyone with known proliferative retinopathy should be examined and monitored before and during rapid glucose lowering.[2]
Taking insulin or a sulfonylurea without dose adjustment
Semaglutide alone rarely causes hypoglycemia, but combined with insulin or a sulfonylurea the risk climbs. The ADA Standards of Care advises reducing the sulfonylurea or insulin dose at initiation and monitoring glucose closely during titration.[2]
Red Flags: When to Call Your Doctor or Go to the ER
The symptoms below are not titration effects and should not be managed by skipping a dose and waiting. Each maps to a specific diagnosis that worsens with delay.
Tell the surgical and anesthesia team that you take semaglutide, and do so at the pre-operative visit, not on the day of the procedure. Slowed gastric emptying means food can remain in the stomach far longer than expected, which raises aspiration risk under sedation. Anesthesia guidance recommends individualized plans that may include holding the drug or switching to a clear-liquid diet beforehand.[4]
How Ozempic Compares With Other GLP-1 Drugs
Side effect profiles across the GLP-1 class are more similar than they are different: every agent in this family causes nausea, vomiting, diarrhea, and constipation, and every one requires gradual dose escalation. What differs is frequency, dosing interval, and the receptor targets involved.
Weekly injection. Single GLP-1 receptor target. Nausea in roughly 1 in 5 patients, with vomiting near 9%. Slowest titration schedule of the major agents: four weeks at each of at least three dose levels before reaching maintenance.
Weekly injection. Dual GIP and GLP-1 receptor agonist. GI side effect rates broadly comparable to semaglutide, with nausea commonly reported in the high teens to low twenties percent range. Often described as better tolerated at equivalent weight-loss efficacy, though head-to-head tolerability data remain limited.
| Drug | Dosing | Mechanism | Hallmark side effect profile |
|---|---|---|---|
| Semaglutide (Ozempic / Wegovy) | Once weekly | GLP-1 receptor agonist | Nausea ~20%, vomiting ~9%, constipation ~6–7% |
| Tirzepatide (Mounjaro / Zepbound) | Once weekly | Dual GIP/GLP-1 agonist | Nausea and diarrhea most common; generally similar GI burden |
| Dulaglutide (Trulicity) | Once weekly | GLP-1 receptor agonist | Nausea, diarrhea, abdominal pain; lower nausea rates than semaglutide in some trials |
| Liraglutide (Victoza / Saxenda) | Once daily | GLP-1 receptor agonist | Nausea, vomiting, diarrhea; daily dosing allows faster dose adjustment |
| Oral semaglutide (Rybelsus) | Once daily, fasting | GLP-1 receptor agonist | Similar GI profile; strict fasting administration requirements |
If intolerable nausea forces a change, switching within the class is reasonable and often successful — individual tolerance varies more between patients than between drugs. Tirzepatide is the usual next step for people who need greater glycemic or weight benefit and can tolerate a comparable GI burden. For anyone whose dominant problem is constipation or reflux rather than nausea, the answer is usually slower titration and bowel management rather than a different molecule. Prior cardiovascular or kidney disease, cost, and formulary coverage typically matter more than side-effect micro-differences when choosing a first agent.
One practical note on compounding: with the semaglutide shortage resolved, compounded versions are no longer broadly permitted, and unapproved compounded products have been associated with dosing errors because patients self-measure in "units" rather than milligrams. If a product's concentration cannot be verified against the FDA label, that is a safety issue independent of side effects.[5]
Frequently Asked Questions
How long do Ozempic side effects last?
Most GI symptoms peak within one to two weeks of each dose increase and improve substantially by weeks eight to twelve at a stable dose. Nausea typically resolves first; constipation often lingers longer. A minority of patients — roughly 5–10% in trials — stop the drug because symptoms never become tolerable.
Do side effects go away if I stop taking Ozempic?
Yes, for the direct pharmacological effects. Semaglutide has a half-life of about one week, so blood levels fall by roughly half each week after the last injection, and nausea, vomiting, and appetite suppression resolve over two to four weeks. Weight gain after stopping is common and reflects the return of baseline appetite rather than a lingering drug effect.
Are side effects worse at higher doses?
Generally yes — GI adverse events are dose-dependent, which is precisely why the label mandates starting at 0.25 mg and escalating in steps. That said, some patients tolerate 2 mg better than they tolerated 0.5 mg, because adaptation has occurred by the time they reach the higher dose. Dose level alone does not predict who will struggle.
Can Ozempic cause hair loss?
Hair thinning is reported but is not a direct drug effect. It is telogen effluvium — a temporary shedding triggered by rapid weight loss, low protein intake, or significant caloric deficit. It usually begins two to three months into treatment and reverses once nutrition and weight stabilize. Prioritizing protein and avoiding crash dieting is the most effective prevention.
Is Ozempic safe to take long term?
Cardiovascular outcome trials extending beyond three years did not reveal unexpected long-term safety signals, and the ADA Standards of Care supports continued use in people with type 2 diabetes and established cardiovascular disease.[2] Longer-term questions remain about lean mass loss, nutritional status, and the effects of indefinite therapy, which is why ongoing monitoring — not just annual labs — is part of good prescribing practice.
Does Ozempic cause thyroid cancer in humans?
It has not been shown to. The boxed warning is based on rodent data showing thyroid C-cell tumors at clinically relevant exposures. Human post-marketing data have not confirmed an increased incidence of medullary thyroid carcinoma, but the warning remains in place and the contraindication for people with a personal or family history of medullary thyroid cancer or MEN2 is absolute.[1]
Can I drink alcohol while taking Ozempic?
There is no absolute prohibition, but alcohol worsens nausea and reflux, adds caloric intake that blunts results, and increases hypoglycemia risk if you also take insulin or a sulfonylurea. Most clinicians advise limiting intake during titration and avoiding it entirely on the days immediately following a dose increase.
What happens if I miss a dose?
If the missed dose is remembered within five days, take it as soon as possible. If more than five days have passed, skip it and resume on the next scheduled day. Do not double up to catch up — that reliably produces a severe GI episode. If you miss several weeks, your clinician will usually restart at a lower dose rather than resuming the maintenance dose directly.
- Nausea (about 20%), diarrhea (about 13%), vomiting (about 9%), and constipation (about 6%) are the most frequent Ozempic side effects, per FDA prescribing information, and they are direct consequences of how GLP-1 receptor agonists work.
- Symptoms peak after each dose increase and generally improve within 8–12 weeks at a stable dose; constipation often outlasts nausea.
- Rare but serious risks include acute pancreatitis, gallbladder disease, bowel obstruction, acute kidney injury from dehydration, and retinopathy complications during rapid glucose lowering.
- Ozempic carries a boxed warning for thyroid C-cell tumors based on rodent data; it is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN2.
- Slower titration, smaller and slower meals, adequate protein and fluids, and early bowel management prevent more discontinuations than switching drugs does.
- Severe abdominal pain radiating to the back, intractable vomiting, and abdominal distension without bowel movements require same-day medical evaluation — and you must tell your anesthesia team before any procedure.
- U.S. Food and Drug Administration. Ozempic (semaglutide) injection, for subcutaneous use: Prescribing Information, including Boxed Warning and Adverse Reactions sections. fda.gov
- American Diabetes Association. Standards of Care in Diabetes—2026. Diabetes Care. Sections on pharmacologic approaches to glycemic treatment and microvascular complications. diabetes.org
- U.S. Food and Drug Administration. Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking GLP-1 receptor agonist medicines (preliminary evaluation, January 2024). fda.gov
- American Society of Anesthesiologists. Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists (2023, with subsequent updates). asahq.org
- MedlinePlus (U.S. National Library of Medicine). Semaglutide Injection: MedlinePlus Drug Information. medlineplus.gov
